Varda Space builds orbital manufacturing systems to produce biologics and other pharmaceutical components that benefit from microgravity-driven crystallization. The company is establishing a 10,000-square-foot laboratory in El Segundo, California to perform process engineering and identify which proteins and antibodies are best suited for space-based production. That lab is intended to generate intellectual property—Varda expects a higher volume of patent filings as it refines crystallization conditions and protocols. Varda has launched and returned three successful missions since 2023 and anticipates completing four missions this year. It has transitioned spacecraft manufacturing in-house after initially housing its manufacturing module inside Rocket Lab vehicles. The company also generates revenue by using its spacecraft as a hypersonic flight testbed for the U.S. Department of Defense, proposing a faster launch-and-return testing cadence and recoverable tested material. Varda operates orbital drug-manufacturing capsules that use microgravity to crystallize pharmaceutical compounds and returned its first capsule after a 10-month mission that successfully reformulated the HIV medicine ritonavir. The company has developed complementary terrestrial methods—including a hyper-gravity crystallization screening platform—and has begun publishing R&D results. Varda plans to scale from a single demonstration mission to a regular cadence of customer payload missions, with the next three already manifested with Rocket Lab and the next launch slated to land in Australia later this year. Leadership says the near-term focus is increasing flight cadence before prioritizing reusability, with capsule refurbishment and larger reactors targeted around 2027. Varda projects per-mission costs to fall from about $12 million for the initial flight to $5–6 million by mission four and roughly $2.5 million or less by mission ten. The company has a handful of signed contracts with publicly traded biotech customers and plans to focus solely on pharmaceuticals for the next decade or more. Varda Space is a startup focused on manufacturing in orbit, aiming to create a factory in space. The core offering is space-based manufacturing infrastructure and processes to produce goods in microgravity. According to the article, the company raised $42 million to support creation of its in-space production facility. The funding is described as enabling the development and construction of that factory. The article does not provide revenue, user metrics, investors, or additional financial details. Varda is building unmanned space-based manufacturing facilities to produce high-dollar-per-unit-mass products that can be brought back to Earth. The company focuses on manufacturing in space for terrestrial applications rather than 3D printing. Early target products mentioned include carbon nanotubes, fiber optic cables, organs and novel materials that could justify high launch costs. Varda was incubated at Founders Fund and is led by CEO and co-founder Will Bruey, a former SpaceX engineer. The firm envisions ramping its platform into broader space-manufacturing infrastructure and ultimately harvesting source materials in space via asteroid mining. Financially, Varda emerged with $9 million in outside funding to support its initial development and operations.

Total raised

$328M

Funding rounds

4

Latest round

Series C

Latest activity

Jul 2025